- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00150631
Danish Hypertension Prevention Project - DHYPP
Danish Hypertension Prevention Project
Studienübersicht
Detaillierte Beschreibung
Essential hypertension, a major health problem worldwide, is a disease generally considered to require life-long treatment. However, evidence suggests that hypertension is caused by specific phenotypic changes caused by a combination of genetic and environmental factors. Thus, in principle, hypertension could be prevented by prevention of these phenotypic changes. Animal data indicate that early treatment that blocks the renin-angiotensin system have long-term effects after treatment withdrawal. The present human study is testing whether early treatment (with the AT1- antagonist) is able to have a persistent effect after stopping treatment.
This is a monocenter, double-blind, randomized, placebo-controlled study in healthy, normotensive (consultation diastolic blood pressure over 2 visits < 85 mmHg) subjects 18 to 36 years of age whose both parents have essential hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass.
Subjects are recruited by use of hospital registers to identify persons who have received the indication essential hypertension, and are of an age that they may have children of the appropriate age. These persons are then mailed asking if they do have children with a partner who is also hypertensive, and asking permission to contact the children. The diagnosis of hypertension of the parents is checked following evaluation by the physicians who are treating them.
One hundred subjects were randomly assigned to one of two treatment groups: placebo; or candesartan cilexetil, 16 mg, once daily. Before inclusion and after 12 months of treatment glomerular filtration rate, renal vascular resistance, echocardiography and 24-hour blood pressure monitoring were performed. Subjects were evaluated at 0.5, 1, 2, 4, 6 and 10 months to ensure compliance and to control blood pressure. After 12-months of treatment, 24-hour blood pressure monitoring were performed in a scheduled manner over a 10-year period. The primary effect parameter is 24-hour blood pressure measured 10 years after withdrawal of treatment. Interim analyses will be made at 1, 2 and 5 years by an independent data committee. Secondary effect parameters will be numbers on antihypertensive treatment at 2, 5 and 10 years after withdrawal, as well as the effect of treatment on renal vascular resistance and left ventricular mass.
A substudy is comparing renal haemodynamics and genetic profil of the subjects with persons having normotensive parents.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Aarhus, Dänemark, 8000
- Karin Skov
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Both parents have essential hypertension
- Age 18 - 36 years
- Caucasians
- Diastolic blood pressure less than 85 mmHg at inclusion time
- Female participants using orale anticonceptives ot intrauterine devices
Exclusion Criteria:
- Clinical or biochemically signs of disease in kidney, liver, or endocrine organs
- Diastolic blood pressure above 85 mmHg at inclusion time
- Pregnancy or pregnancy wish
- Daily medication, except for orale anticoncetives -
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: active (candesartan)
12 mo treatment with candesartan
|
placebo controlled double blind
Andere Namen:
|
Placebo-Komparator: placebo
12 mo placebo treatment
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
The primary outcome is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension.
Zeitfenster: 10 years
|
10 years
|
Secondary outcomes are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass.
Zeitfenster: 1 year
|
1 year
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: michael mulvany, prof, Dept. of Pharmacology, Aarhus University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20000114
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hypertonie
-
Nantes University HospitalBeendetZirrhotischer Patient mit Verdacht auf portale Hypertension und im Rahmen eines OV-ScreeningsFrankreich
Klinische Studien zur Candesartan
-
St. Olavs HospitalUllevaal University Hospital; University Hospital of North Norway; Norwegian University... und andere MitarbeiterAktiv, nicht rekrutierend
-
AstraZenecaAbgeschlossenPrimäre HypertonieRumänien
-
The Netherlands Cancer InstituteRoche Pharma AG; AstraZenecaAbgeschlossen
-
EMSZurückgezogenEssentielle arterielle Hypertonie
-
Montreal Heart InstituteAstraZenecaAbgeschlossen
-
Kyorin UniversityMinistry of Health, Labour and Welfare, JapanUnbekanntNiere, polyzystisch, autosomal dominantJapan
-
Yonsei UniversityAbgeschlossenAlkoholische LebererkrankungKorea, Republik von
-
Technische Universität DresdenAbgeschlossenGesunde ProbandenDeutschland
-
BayerAbgeschlossenBluthochdruck, wesentlichDeutschland